Ad
related to: klonopin dosage and administration guide printable free
Search results
Results From The WOW.Com Content Network
Clonazepam, sold under the brand name Klonopin among others, is a benzodiazepine medication used to prevent and treat anxiety disorders, seizures, bipolar mania, agitation associated with psychosis, obsessive–compulsive disorder (OCD), and akathisia. [11] It is a long-acting [12] tranquilizer of the benzodiazepine class. [11]
The first ODT form of a drug to get approval from the U.S. Food and Drug Administration (FDA) was a Zydis ODT formation of Claritin in December 1996. [19] It was followed by a Zydis ODT formulation of Klonopin ( clonazepam ) in December 1997, [ 20 ] and a Zydis ODT formulation of Maxalt ( rizatriptan ) in June 1998. [ 21 ]
Clobazam is widely used by specialist epilepsy clinics worldwide and clonazepam is popular in the Netherlands, Belgium and France. [59] Clobazam was approved for use in the United States in 2011. In the UK, both clobazam and clonazepam are second-line choices for treating many forms of epilepsy. [60]
Tablets of the drug clonazepam, the generic name for Klonopin, which is used to treat epilepsy, panic disorder and muscle spasms, have been recalled for incorrect labeling that could inadvertently ...
Cloniprazepam is a benzodiazepine derivative and a prodrug of clonazepam, 7-aminoclonazepam, and other metabolites. [ 1 ] [ 2 ] Some of the minor metabolites include 3-hydroxyclonazepam and 6-hydroxyclonazepam , 3-hydroxycloniprazepam and ketocloniprazepam with ketone group formed where 3-hydroxy group was.
In the United States, the Food and Drug Administration (FDA) determines the requirements for patient package inserts. In the United States, the FDA will occasionally issue revisions to previously approved package inserts, in much the same way as an auto manufacturer will issue recalls upon discovering a problem with a certain car.
Repeated administration of a medication is also different from single dosing, as many drugs have active metabolites that can build up in the body. [6] Patient variables such as sex, age, and organ function may also influence the effect of the drug on the system. These variables are rarely included in equianalgesic charts. [7] [3] [8]
The consensus is to reduce dosage gradually over several weeks, e.g. 4 or more weeks for diazepam doses over 30 mg/day, [1] with the rate determined by the person's ability to tolerate symptoms. [120] The recommended reduction rates range from 50% of the initial dose every week or so, [121] to 10–25% of the daily dose every 2 weeks. [120]